Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2024 08:00 ET | Source: Araris Biotech AG

Araris Biotech AG Appoints Dr. Ulf Grawunder to Scientific Advisory Board

AU ZH, Switzerland, June 13, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the...
April 05, 2024 15:00 ET | Source: Araris Biotech AG

Araris Biotech AG Presents Data on Novel Antibody-Drug Conjugates at American Association for Cancer Research (AACR) Annual Meeting 2024

AU ZH, Switzerland, April 05, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced...
March 06, 2024 08:00 ET | Source: Araris Biotech AG

Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024

AU ZH, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced...
November 08, 2023 02:00 ET | Source: Araris Biotech AG

Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris’ Proprietary Linker-Conjugation Technology

AU ZH, Switzerland, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they...
October 04, 2023 08:00 ET | Source: Araris Biotech AG

Araris Biotech AG Initiates Leadership Transition to Advance Next Evolution of Growth in its Antibody-Drug Conjugate (ADC)-Pipeline

ZURICH, SWITZERLAND, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris”), a company developing ADCs using its proprietary linker-payload technology, today announced the appointment of...
May 05, 2023 02:00 ET | Source: Araris Biotech AG

Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates

Innosuisse supports 53 companies out of 752 applications with total CHF 112MAraris’ awarded grant will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC)...
April 17, 2023 10:00 ET | Source: Araris Biotech AG

Araris Biotech AG Acquires ARS Pharmaceutical’s Nectin-4 Antibody

AU ZH, Switzerland, April 17, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the execution of an...
April 14, 2023 12:00 ET | Source: Araris Biotech AG

Araris Biotech AG Presents Preclinical Data Highlighting Stable and Efficacious Low Drug-Load ADCs at American Association for Cancer Research (AACR) Annual Meeting 2023

AU ZH, Switzerland, April 14, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will deliver...
April 11, 2023 22:00 ET | Source: Araris Biotech AG

Araris Biotech AG Announces Strategic Investment with Samsung Ventures

Samsung Ventures makes investment in ArarisProceeds will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates AU ZH, Switzerland, April 11, 2023...
March 14, 2023 16:40 ET | Source: Araris Biotech AG

Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2023

ZURICH, Switzerland, March 14, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced it will be presenting...